TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00000883
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03539328
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy medication
Study: NCT00555230
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Study: NCT00555230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Study: NCT02678143
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01809171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampoule
Study: NCT03487107
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT03487107
Drug: DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule administered orally once daily
Study: NCT02344992
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study: NCT01051505
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
Study: NCT01051505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
Study: NCT03266237
Drug: Vaxigrip®
Approvals — FDA: no, EMA: no, PMDA: no
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
Study: NCT03166735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00322803
Drug: ELB139
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01989091
Drug: Heparin 5,000 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Catheter Lock Solution
Study: NCT01490944
Drug: Iron and Folic Acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
Study: NCT00148681
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 3 weeks for 12 weeks
Study: NCT00148681
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously every 3 weeks for 12 weeks
Study: NCT01728909
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT02958111
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
Study: NCT01781637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT01099137
Drug: Sulphonylurea dose-up
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
Study: NCT00584298
Drug: SMS995
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00584298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03354026
Drug: AICH-PXZY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Study: NCT03354026
Drug: AICH-without PXZY
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Study: NCT03354026
Drug: AICH-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is made up of Starch, bitter taste and cyclodextrin
Study: NCT01085045
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo administered as two puffs BID for 7 days
Study: NCT04223895
Drug: CKD-386 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT04223895
Drug: D012, D326 and D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
Study: NCT02245438
Drug: Norethindrone-Ethinyl Estradiol
Normalized name: norethindrone-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02592551
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
Study: NCT02839408
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet containing 500mg Azithromicyn
Study: NCT04669132
Drug: Palonesetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Palonosetron 0.56 mg, once daily, on chemotherapy day;
Study: NCT01519271
Drug: Placebo Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
Study: NCT01458912
Drug: Placebo matching Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs a.m. via Respimat inhaler
Study: NCT00803764
Drug: Naproxen Tablets, 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02303548
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02576353
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Sublingual Spray (FSS)
Study: NCT02576353
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Citrate IV (FCIV)
Study: NCT01361802
Drug: Placebo Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Spray
Study: NCT02321384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Study: NCT02321384
Drug: RO6889678
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Study: NCT04091854
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Study: NCT00218205
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02400047
Drug: Ketoprofen 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
Study: NCT02012244
Drug: fentanyl-based analgesia
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
Study: NCT01377025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets in the morning and two in the evening.
Study: NCT04512053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration for 12 weeks, once daily
Study: NCT01631981
Drug: Placebo + Primolut-Nor 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up.
Study: NCT01731990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of Canakinumab
Study: NCT04426669
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
Study: NCT04388839
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 60 minutes with dosing ranging from 220mg to 1200mg
Study: NCT04388839
Drug: Cyclophosphamide Pill
Normalized name: cyclophosphamide Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on Body Surface Area (BSA) round to nearest 25mg
Study: NCT01667536
Drug: Drug: 99mTc-MIP-1404
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
Study: NCT02171754
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00795015
Drug: insulin regular IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
Study: NCT00979706
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year.
Study: NCT00979706
Drug: HAART + Immunotherapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year.
Study: NCT01950247
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01203878
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 4 weeks after completion of imiquimod therapy
Study: NCT03277742
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS plus standard DM2 care
Study: NCT04205968
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV bolus or IV
Study: NCT04205968
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04205968
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02679014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Study: NCT02679014
Drug: RO5459072
Approvals — FDA: no, EMA: no, PMDA: no
Description: With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Study: NCT01471093
Drug: OPC-12759 Ophthalmic solution
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2％ OPC-12759 Ophthalmic solution
Study: NCT01471093
Drug: OPC-12759 Ophthalmic suspension
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2％ OPC-12759 Ophthalmic suspension
Study: NCT01735279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
Study: NCT02841488
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of patient controlled analgesia device with intravenous fentanyl
Study: NCT01538251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Study: NCT03105830
Drug: iv paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv paracetamol
Study: NCT02671435
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of mFOLFOX as stated in arm description.
Study: NCT03073785
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03073785
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03073785
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01848301
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion in the coronary artery to study endothelial function
Study: NCT02293083
Drug: trigger point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00193284
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03097900
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
Study: NCT03068741
Drug: Comparison 1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedics will administer an identical volume of reconstituted intramuscular placebo.
Study: NCT03068741
Drug: Comparison 2: Liberal fluids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
Study: NCT03068741
Drug: Comparison 2: Conservative fluids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
Study: NCT03193190
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin will be administered as per the schedule specified in the respective arm.
Study: NCT03193190
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered as per the schedule specified in the respective arm.
Study: NCT03193190
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 will be administered as per the schedule specified in the respective arm.
Study: NCT03193190
Drug: AB928
Normalized name: Adenosine A2a and A2b receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB928 will be administered as per the schedule specified in the respective arm.
Study: NCT04666636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
Study: NCT00912288
Drug: Placebo po TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched to Dimebon) po for 26 weeks
Study: NCT02992678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
Study: NCT03755609
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1ug/kg intravenously
Study: NCT03340727
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
Study: NCT03340727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
Study: NCT00619970
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo TID x 10days
Study: NCT03078075
Drug: Placebo (PLB) Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: once-daily oral placebo tablets
Study: NCT01299376
Drug: L50/H12.5/A5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299376
Drug: L50/H12.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299376
Drug: Placebo to L50/H12.5/A5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299376
Drug: Placebo to L50/H12.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240981
Drug: Topical testosterone gel 1% (active formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
Study: NCT02989389
Drug: LY3323795
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04067102
Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
Study: NCT04067102
Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
Study: NCT02989389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00988026
Drug: Minocycline vs Lymecycline
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Study: NCT02300948
Drug: PregVit® contains 1.1 mg of folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Study: NCT02300948
Drug: PregVit-folic 5® contains 5 mg of folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Study: NCT00528580
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg once daily PO/NG x 4 days
Study: NCT03472365
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Study: NCT00957047
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily placebo comparator
Study: NCT01182415
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
Study: NCT01515137
Drug: Erlotinib plus sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).